FDA, CDER Discuss AI/ML In Drug Development In Discussion Papers
FDA hopes to engage in “mutual learning” with stakeholders to develop new regulations for the use of AI/ML drug development.
You may also be interested in...
Nuray Yurt, Merck’s business engagement and activation lead for digital data and analytics, told In Vivo about her hopes for the future of AI regulation and how stakeholders ought to reframe their understanding of the sector.
The White House Office of Science and Technology Policy has released an updated national strategic framework outlining priorities and goals for federal investment in AI. Industry executive Peter Shen weighs in on the plan.
News We’re Watching: Smart Watch Blood Glucose Warning, $100M For Women’s Health, Zimmer Surgical Robot Clearance
This week, the FDA reminded consumers that smart watches and rings are not blood glucose monitors; First Lady Jill Biden announced a $100M women’s health initiative; and the Zimmer ROSA Shoulder System got FDA clearance.